PRP treatment belongs to the medical field of regenerative medicine. The therapeutic objective is to deliver concentrated signaling proteins—including platelet-derived growth factor and vascular endothelial growth factor—directly into target tissues. These proteins activate quiescent stem cells, improve localized microcirculation, and stimulate structural protein synthesis in the skin and scalp.

PRP treatment is an outpatient medical procedure lasting 45 to 60 minutes. Peripheral blood (10 to 60 mL) is collected in specialized tubes containing anti-coagulants. The blood undergoes controlled centrifugation to separate red blood cells, platelet-poor plasma, and the target platelet-rich layer. The isolated PRP is drawn into micro-syringes and injected intradermally or subdermally at 1-centimeter intervals using tiny 30-gauge needles or automated delivery devices. Optional topical numbing reduces procedural discomfort.

• Autologous safety profile: Derived entirely from the patient's own blood, minimizing immunogenic or allergic responses.
• Follicular stimulation: Increases microvascular supply around miniaturized hair follicles, extending the active growth phase.
• Dermal remodeling: Stimulates fibroblasts to synthesize type I collagen and elastin in aging skin.
• Minimal downtime: Outpatient delivery allows rapid return to daily activities within 24 hours.
• Synergistic potential: Complements existing therapies such as topical minoxidil, oral anti-androgens, microneedling, and laser resurfacing.

Immediate post-treatment swelling and erythema (redness) peak within 24 hours and resolve within 48 to 72 hours. Patients resume non-strenuous daily work immediately. Strenuous exercise, hair washing, and direct UV exposure are restricted for 24 hours. Measurable hair density increases and skin texture improvements appear between 3 and 6 months following initial treatment.

PRP treatment is clinically indicated for androgenetic alopecia (pattern hair loss in men and women), telogen effluvium (excessive hair shedding), facial rhytids (fine lines and wrinkles), post-acne scarring, photoaging, and skin texture irregularities.

Patients must avoid nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and naproxen for 7 to 14 days before treatment, as these agents impair platelet aggregation and growth factor release. Adequate systemic hydration (drinking 1 to 2 liters of water daily) for 48 hours prior ensures optimal plasma yield during centrifugation. Patients should refrain from alcohol and heavy smoking for at least 72 hours prior to the procedure.

PRP carries a low risk profile due to its autologous origin. Transient side effects include mild injection-site discomfort, swelling, erythema, localized bruising, and temporary tightness. Rare complications include superficial skin infection, transient localized headache, minor nerve irritation, or panniculitis (inflammation of subcutaneous fat).

The clinical journey begins with a diagnostic evaluation including hair density measurements or skin analysis. On the day of treatment, blood is drawn via standard venipuncture and centrifuged to isolate the platelet-rich plasma layer. Following topical or local anesthesia, the concentrated PRP is reinjected into the targeted dermal or scalp tissue. Patients recover quickly, with post-procedure follow-ups scheduled at 4- to 6-week intervals across a multi-session treatment series.